Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
20
NCT03427073
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 27, 2015
Completion: Mar 13, 2017